Biophytis S.A. Files 6-K Report
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Biophytis S.A. filed a 6-K on 10/31/25, confirming foreign private issuer status.
AI Summary
On October 31, 2025, Biophytis S.A. filed a Form 6-K with the SEC. The filing indicates that Biophytis S.A. is a foreign private issuer and is submitting its report under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The company's principal executive office is located at Sorbonne University in Paris, France.
Why It Matters
This filing provides an update on Biophytis S.A.'s regulatory reporting status as a foreign private issuer. It confirms their adherence to SEC reporting requirements.
Risk Assessment
Risk Level: low — This filing is a routine regulatory submission and does not contain new financial or operational information that would typically indicate significant risk.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Stanislas Veillet (person) — Contact Person
- Sorbonne University (company) — Company Address
- October 31, 2025 (date) — Filing Date
FAQ
What type of filing is this for Biophytis S.A.?
This is a Form 6-K report, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was this report filed?
The report was filed on October 31, 2025.
Where is Biophytis S.A.'s principal executive office located?
Biophytis S.A.'s principal executive office is located at Sorbonne University—BC 9, Bâtiment A 4ème étage, 4 place Jussieu, 75005 Paris, France.
Does Biophytis S.A. file annual reports under Form 20-F or Form 40-F?
Biophytis S.A. indicates it files annual reports under cover of Form 20-F.
What is the Commission File Number for Biophytis S.A.?
The Commission File Number for Biophytis S.A. is 001-38974.
Filing Stats: 247 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-10-31 09:22:57
Filing Documents
- tm2529942d1_6k.htm (6-K) — 10KB
- tm2529942d1_ex99-1.htm (EX-99.1) — 108KB
- tm2529942d1_ex99-1img001.jpg (GRAPHIC) — 63KB
- tm2529942d1_ex99-1img002.jpg (GRAPHIC) — 195KB
- tm2529942d1_ex99-1img003.jpg (GRAPHIC) — 101KB
- tm2529942d1_ex99-1img004.jpg (GRAPHIC) — 101KB
- tm2529942d1_ex99-1img005.jpg (GRAPHIC) — 100KB
- tm2529942d1_ex99-1img006.jpg (GRAPHIC) — 257KB
- tm2529942d1_ex99-1img007.jpg (GRAPHIC) — 240KB
- tm2529942d1_ex99-1img008.jpg (GRAPHIC) — 212KB
- tm2529942d1_ex99-1img009.jpg (GRAPHIC) — 185KB
- tm2529942d1_ex99-1img010.jpg (GRAPHIC) — 170KB
- tm2529942d1_ex99-1img011.jpg (GRAPHIC) — 198KB
- tm2529942d1_ex99-1img012.jpg (GRAPHIC) — 205KB
- tm2529942d1_ex99-1img013.jpg (GRAPHIC) — 187KB
- tm2529942d1_ex99-1img014.jpg (GRAPHIC) — 130KB
- tm2529942d1_ex99-1img015.jpg (GRAPHIC) — 124KB
- tm2529942d1_ex99-1img016.jpg (GRAPHIC) — 88KB
- tm2529942d1_ex99-1img017.jpg (GRAPHIC) — 144KB
- tm2529942d1_ex99-1img018.jpg (GRAPHIC) — 234KB
- tm2529942d1_ex99-1img019.jpg (GRAPHIC) — 245KB
- tm2529942d1_ex99-1img020.jpg (GRAPHIC) — 158KB
- tm2529942d1_ex99-1img021.jpg (GRAPHIC) — 151KB
- tm2529942d1_ex99-1img022.jpg (GRAPHIC) — 140KB
- tm2529942d1_ex99-1img023.jpg (GRAPHIC) — 179KB
- tm2529942d1_ex99-1img024.jpg (GRAPHIC) — 185KB
- tm2529942d1_ex99-1img025.jpg (GRAPHIC) — 184KB
- tm2529942d1_ex99-1img026.jpg (GRAPHIC) — 112KB
- tm2529942d1_ex99-1img027.jpg (GRAPHIC) — 149KB
- tm2529942d1_ex99-1img028.jpg (GRAPHIC) — 178KB
- tm2529942d1_ex99-1img029.jpg (GRAPHIC) — 199KB
- tm2529942d1_ex99-1img030.jpg (GRAPHIC) — 189KB
- tm2529942d1_ex99-1img031.jpg (GRAPHIC) — 207KB
- tm2529942d1_ex99-1img032.jpg (GRAPHIC) — 134KB
- tm2529942d1_ex99-1img033.jpg (GRAPHIC) — 148KB
- tm2529942d1_ex99-1img034.jpg (GRAPHIC) — 174KB
- 0001104659-25-104698.txt ( ) — 7861KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOPHYTIS S.A. Date: October 31, 2025 By: Name: Stanislas Veillet Title: Chairman and Chief Executive Officer